Corbus Pharmaceuticals Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | ||
| Date: March 9, 2026 | By: | /s/ YUVAL COHEN |
|---|---|---|
| Name: | Yuval Cohen | |
| Title: | Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ YUVAL COHEN | Chief Executive Officer and Director(Principal Executive Officer) | March 9, 2026 |
| Yuval Cohen | ||
| /s/ SEAN MORAN | Chief Financial Officer(Principal Financial and Accounting Officer) | March 9, 2026 |
| Sean Moran | ||
| /s/ RACHELLE JACQUES | Chair of the Board | March 9, 2026 |
| Rachelle Jacques | ||
| /s/ ANNE ALTMEYER | Director | March 9, 2026 |
| Anne Altmeyer | ||
| /s/ YONG BEN | Director | March 9, 2026 |
| Yong Ben | ||
| /s/ JOHN JENKINS | Director | March 9, 2026 |
| John Jenkins | ||
| /s/ WINSTON KUNG | Director | March 9, 2026 |
| Winston Kung | ||
INDEX TO FINANCIAL STATEMENTS
| Page Number | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Corbus Pharmaceuticals Holdings, Inc. Financial Statements-December 31, 2025: | |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.